Post partum and non-post partum relapsing Graves' hyperthyroidism display different response to anti-thyroid drugs

COMMENTED

Thyroid

The long-term outcome of treatment for Graves' hyperthyroidism

Thyroid.

Sjölin G, Holmberg M, Törring O, Byström K, Khamisi S, de Laval D, Abraham-Nordling M, Calissendorff J, Lantz M, Hallengren B, Filipsson Nyström H, Wallin G

doi: 10.1089/thy.2019.0085.

Thyroid

Increased remission rates after long-term methimazole therapy in patients with Graves' disease: Results of a randomized clinical trial

Thyroid.

Azizi F, Amouzegar A, Tohidi M, Hedayati M, Khalili D, Cheraghi L, Mehrabi Y, Takyar M

doi: 10.1089/thy.2019.0180.

COMMENTED

Thyroid

Differences in Diagnostic Criteria Mask the True Prevalence of Thyroid Disease in Pregnancy - A Systematic Review and Meta-Analysis

Thyroid.

Dong A, Stagnaro-Green A

doi: 10.1089/thy.2018.0475.

Thyroid

Differences in Thyroid Nodule Cytology and Malignancy Risk between Children and Adults

Thyroid.

Cherella CE, Angell TE, Richman DM, Frates MC, Benson CB, Moore FD Jr, Barletta JA, Hollowell M, Smith JR, Alexander EK, Cibas ES, Wassner AJ

doi: 10.1089/thy.2018.0728.

COMMENTED

Thyroid

Recurrence after low-dose radioiodine ablation and recombinant human thyroid-stimulating hormone for differentiated thyroid cancer (HiLo): long-term results of an open-label, non-inferiority randomised controlled trial

Lancet Diabetes Endocrinol.

Dehbi HM, Mallick U, Wadsley J, Newbold K, Harmer C, Hackshaw A

doi: 10.1016/S2213-

COMMENTED

Thyroid

Primary therapy of Graves' disease and cardiovascular morbidity and mortality: a linked-record cohort study

Lancet Diabetes Endocrinol.

Okosieme OE, Taylor PN, Evans C, Thayer D, Chai A, Khan I, Draman MS, Tennant B, Geen J, Sayers A, French R, Lazarus JH, Premawardhana LD, Dayan CM

doi: 10.1016/S2213-8587(19)30059-2.

Thyroid

Higher TSH is not associated with thyroid cancer risk in the presence of thyroid autoimmunity

J Clin Endocrinol Metab.

Paparodis RD, Bantouna D, Karvounis E, Imam S, Jaume JC

doi: 10.1210/clinem/dgaa237.

Type 2 DiabetesThyroidFurther Publications

Active Moderate-to-Severe Graves' Orbitopathy in a Patient With Type 2 Diabetes Mellitus and Vascular Complications

Front Endocrinol (Lausanne).

Urselli F, Pontieri G, Peschi L, Liccardi A, Ruggiero AR, Biondi B

doi: 10.3389/fendo.

Further Publications

Cortisol and aldosterone responses to hypoglycemia and Na depletion in women with non-classic 21-hydroxylase deficiency

J Clin Endocrinol Metab.

Kamenický P, Blanchard A, Lamaziere A, Piedvache C, Donadille B, Duranteau L, Bry H, Gautier JF, Salenave S, Raffin-Sanson ML, Genc S, Pietri L, Christin-Maitre S, Thomas J, Lorthioir A, Azizi M, Chanson P, Le Bouc Y, Brailly-Tabard S, Young J

doi: 10.1210/clinem/dgz005.

Related content

The long-term outcome of treatment for Graves' hyperthyroidism

Increased remission rates after long-term methimazole therapy in patients with Graves' disease: Results of a randomized clinical trial

Differences in Diagnostic Criteria Mask the True Prevalence of Thyroid Disease in Pregnancy - A Systematic Review and Meta-Analysis

Differences in Thyroid Nodule Cytology and Malignancy Risk between Children and Adults

Recurrence after low-dose radioiodine ablation and recombinant human thyroid-stimulating hormone for differentiated thyroid cancer (HiLo): long-term results of an open-label, non-inferiority randomised controlled trial

Primary therapy of Graves' disease and cardiovascular morbidity and mortality: a linked-record cohort study

Higher TSH is not associated with thyroid cancer risk in the presence of thyroid autoimmunity

Active Moderate-to-Severe Graves' Orbitopathy in a Patient With Type 2 Diabetes Mellitus and Vascular Complications

Cortisol and aldosterone responses to hypoglycemia and Na depletion in women with non-classic 21-hydroxylase deficiency